Kolexia
Ghiringhelli Francois Médecine interne
Ghiringhelli Francois
Médecine interne
Centre Georges-François Leclerc
Dijon, France
608 Activités
82 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du poumon Métastase tumorale Tumeurs du côlon Adénocarcinome Carcinomes Tumeurs du sein Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules

Collaborateurs

Voir plus
Ladoire Sylvain
Ladoire Sylvain
Centre Georges-François Leclerc, Dijon, France
Borg Christophe
Borg Christophe
Hôpital Nord Franche-Comté, Montbéliard, France
Derangere Valentin
Derangere Valentin
Centre Georges-François Leclerc, Dijon, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
MSD
28 collaboration(s)
Dernière en 2023
Merck-Serono
12 collaboration(s)
Dernière en 2023
Amgen
11 collaboration(s)
Dernière en 2023
AstraZeneca
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MOUNTAINEER-03: An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Essai Clinique (Seagen)   15 mars 2024
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer: Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease
Essai Clinique (Mayo Clinic)   14 mars 2024
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Essai Clinique (DeuterOncology)   13 mars 2024
COPERNIC: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
Essai Clinique (Roche)   13 mars 2024
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
iintune-1: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Takeda Pharmaceutical)   07 mars 2024
HERIZON-GEA-01: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Essai Clinique (Jazz Pharmaceuticals)   04 mars 2024
HER2: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Essai Clinique (Enliven Therapeutics)   01 mars 2024
IMMUNOPBMC: An Experimental Medicine, Low Grade Interventional, Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Advanced Solid Tumours
Essai Clinique (Servier)   20 février 2024
GUIDE2REPAIR: Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment
Essai Clinique (AstraZeneca)   12 février 2024